1[1]Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med, 1999; 340(11): 825～ 831
2[2]Fass R, Ofman JJ. Gastroesophageal reflux disease-should we adopt a new conceptual framework? Am J Gastroenterol, 2002;97(8): 1901 ～ 1909
3[3]Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med, 2002;347(15): 1175～ 1186
4[4]McColl KE, el - Nujumi AM, Chittajallu RS, et al. A study of the patho genesis of Helicobacter pylori negative chronic duodenal ulceration. Gut,1993;34(6): 762～768
5[5]el - Omar E, Penman I, Ardill JE, et al. A substantial proportion of non ulcer dyspepsia patients have the same abnormality of acid secretion as duodenal ulcer patients. Gut, 1995;36(4): 534 ～ 538
6[6]McColl K, Murray L, El - Omar E, et al. Symptomatic benefit from erad icating Helicobacter pylori infection in patients with nonulcer dyspepsia. N EnglJ Med, 1998;339(26): 1869～1874
7[7]BlumAL, Talley NJ, O' Morain C, etal. Lack of effect of treating Heli cobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment(OCAY) Study Group. N Engl J Med, 1998;339(26): 1875 ～ 1881
8[8]Zhang Q, Lehmann A, Rigda R, et al. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro - oesophageal reflux disease. Gut, 2002;50(1): 19 ～ 24
9[9]Spechler SJ, Lee E, Ahnen D, et al. Long -term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow - up of a ran domized controlled trial. Jama, 2001;285(18): 2331 ～ 2338
10[10]Triadafilopoulos G, DiBaise JK, Nostrant TI, et al. The Stretta procedure for the treatment of GERD: 6 and 12 month follow - up of the U.S. open label trial. Gastrointest Endosc, 2002;55(2): 149 ～ 156
